AzTrials
AzTrials

TuberculosisPhase 4NCT00412009

Investigation of a Novel Approach to Improve Treatment Success Rates for Tuberculosis Patients in Senegal

A Phase 4 study testing Comprehensive package of activities in people with Tuberculosis, run by Institut de Recherche pour le Developpement at 1 site in Senegal.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Tuberculosis (TB) patients who receive inadequate treatment or do not complete therapy are more likely to remain infectious, thus contributing to the continuous spread of TB infection in communities. Read more about this study

Who is it for?
Ages 15 to 65 years
Conditions the study is for
Tuberculosis
What is being tested?
Comprehensive package of activities
Type of treatment
Surgery or procedure
How many people
1,500 participants
Where
1 siteSenegal
Study dates
May 2003to Jan 2005
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 15 to 65 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • newly diagnosed sputum-smear positive pulmonary TB (at least two positive specimens), aged 15 years or more, and living in the district served by the District Health Centre.

Who cannot join

  • Smear-negative tuberculosis cases
  • extra-pulmonary tuberculosis cases
  • TB re-treatment cases

Trial locations and contacts

1 site in 1 country.

Senegal1 site
  • Programme National de Lutte Anti-tuberculeuse

    Dakar

Other trials in Senegal

About this study

Official title: Investigation of a Novel Approach to Improve Adherence to Treatment and Treatment Success Rates for Tuberculosis Patients in Senegal

Tuberculosis (TB) patients who receive inadequate treatment or do not complete therapy are more likely to remain infectious, thus contributing to the continuous spread of TB infection in communities. Despite the widespread use of Directly Observed Therapy, defaulters remain an important problem in TB control programmes. In Sénégal, defaulters rate reach 30%, which is hampering dramatically the effectiveness of control. New strategies to deliver treatment to TB patients and ensure proper adherence that are adapted to the local situations are urgently needed.

Objectives

Read more

The overall objective of the project is to improve tuberculosis treatment success rates in Sénégal. The specific objectives are:

  1. to assess the current situation of tuberculosis (TB) in Sénégal
  2. to identify the determinants of cure,
  3. to develop measures to improve patient's compliance with the treatment that are adapted to the local situation, acceptable, affordable and sustainable
  4. to evaluate the impact of these measures on TB control.

Methods

The proposed research seeks to develop and test innovative methods to improve cure rates in TB patients. It will explore the factors of success of TB treatment using inter-disciplinary approach, integrating social sciences and economic analyses into TB research. The project is composed of 3 comprehensive phases:

  • Phase 1: baseline assessment of the TB situation.
  • Phase 2: anthropological study, investigating various domains contributing to patients cure using a range of qualitative research methods. At the end of this investigation, it is expected that determinants of care will be clearly identified. On this basis, suitable methods for improving patients' adherence to treatment will be tailored and developed.
  • Phase 3: these methods will be tested and compared using a cluster randomised controlled trial design, in populations served by defined health centres. Their efficacy will be measured in terms of improvement of the classical TB control programme indicators (cure rate, defaulter rate, failure rate, death rates). The methods will also be evaluated on their acceptability by the TB patients and the communities and on their feasibility (duration : 24 months).

Expected results:

Methods to improve patients' adherence to treatment that are affordable, acceptable and sustainable will be developed and tested according to qualitative and quantitative criteria.

Read the detailed description

General Project Methods

The proposed research seeks to develop and test innovative methods to improve treatment success rates in TB patients in Senegal. It will explore the factors of success of TB treatment using inter-disciplinary approach, integrating social sciences and economic analyses into TB research. The project is composed of 3 comprehensive phases, that will be run concurrently and complement each other:

  • Phase 1: baseline assessment of the TB situation. It is first proposed to assess the magnitude of the TB problem and of the means to control it through a standard baseline assessment (6 months).
  • Phase 2: anthropological study, investigating various domains contributing to patients cure (the patients, the community, the general health services, the policy makers and the TB control staff), using a range of qualitative research methods (12 months). At the end of this investigation, it is expected that determinants of care will be clearly identified with a comprehensive understanding of their relation/interface. On this basis, suitable methods for improving patients' adherence to treatment will be developed.
  • Phase 3: these methods will be tested and compared using a cluster randomised controlled trial design, in populations served by defined health centres. Their efficacy will be measured in terms of improvement of the classical TB control programme indicators (cure rate, defaulter rate, failure rate, death rates). The methods will also be evaluated on their acceptability by the TB patients and the communities and on their feasibility (24 months).

Methods of the Intervention Trial:

The intervention is intended to improve access to care and increase adherence to treatment, targeting simultaneously DHC staff, TB patients and communities, and includes four components:

  1. improving communication between health personnel and patients through appropriate training;
  2. decentralising treatment to remote health posts and involving community health workers (CHW);
  3. strengthening the DOT strategy by giving patients the opportunity to choose their treatment supporter; and
  4. reinforcing supervision of health posts by the DHC team.

The intervention is applied at the District Health Centre (DHC) level, which is the unit of randomisation.

Sample Size:

Based on the detection of an average of 100 new TB cases per DHC per year, an estimated coefficient of variability k=0.12, an estimated success rate in the control arm of 65% using conventional TB control programmes procedures, with 80% power and a type I error of 5%, the required sample size aiming to detect a difference of at least 15% in the treatment success rate between the intervention and control arms is eight DHCs per arm. In order to take into account the variation in recruitment of TB patients between the DHCs, the randomisation is stratified on baseline detection rate of sputum smear positive cases in 2001, that were classified as less than 60/100 000 and more than or equal to 60/100 000.

Patients and follow-up DHCs with a functional TB diagnosis and treatment unit, where no other research projects were being undertaken, were eligible for inclusion. The study population consisted of all individuals presenting to the DHC between June 2003 and May 2004 with newly diagnosed sputum-smear positive pulmonary TB (at least two positive specimens), aged 15 years or more, and living in the district served by the DHC. Written informed consent was obtained at recruitment and patients were followed-up during the course of their eight month treatment regimen, with the last patients seen in January 2005.

Smear-negative and extra-pulmonary tuberculosis cases, as well as re-treatment cases, were not eligible for the study. Patients were recruited into the study between June 2003 and May 2004 and followed up till January 2005.

Endpoints:

Primary endpoints are both the proportion of recruited patients experiencing treatment success (those cured + those completing treatment), and the proportion of patients defaulting from treatment before completion. A "cured" patient is defined by a negative sputum-smear at eight months and on at least one previous occasion. Patients "completing treatment" are those missing smear results but who had finished their treatment regimen. A "defaulter" is defined as a patient who definitely stopped treatment before completion.

Conditions
Tuberculosis
Being tested
Comprehensive package of activities
Keywords
tuberculosis, control, treatment, adherence
Medical subject headings
Tuberculosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Comprehensive package of activitiesProcedure or surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. TB treatment success rate (cure + completed treatment)

  2. Treatment defaulting rates

Secondary outcomes (2)
  1. treatment failure rate

  2. death rate

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Dec 2006 (estimated)
  2. Study startMay 2003
  3. Study completionJan 2005

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,500 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00412009
Sponsor's protocol ID
PAL+ 2671
Status last verified
Dec 2006
First submitted
14 Dec 2006
Last updated
15 Dec 2006
Results posted
No

Publications

  • Lienhardt C, Ogden JA. Tuberculosis control in resource-poor countries: have we reached the limits of the universal paradigm? Trop Med Int Health. 2004 Jul;9(7):833-41. doi: 10.1111/j.1365-3156.2004.01273.x.

    PubMed 15228495
  • Thiam S, LeFevre AM, Hane F, Ndiaye A, Ba F, Fielding KL, Ndir M, Lienhardt C. Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA. 2007 Jan 24;297(4):380-6. doi: 10.1001/jama.297.4.380.

    PubMed 17244834

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Comprehensive package of activities in people with Tuberculosis, run by Institut de Recherche pour le Developpement at 1 site in Senegal.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Dec 2006. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Senegal. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

TB treatment success rate (cure + completed treatment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00412009, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2006.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in